COMMUNIQUÉS West-GlobeNewswire

AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9
10/10/2025
Research Triangle Park, N.C., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle muscular dystrophy (LGMD) 2I/ [...]
Preeminent SOL Treasury Vehicle, Solana Company (NASDAQ:HSDT), Adds Coinbase, BitGo, and Anchorage Digital as Custodians
10/10/2025
NEWTOWN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Solana Company, (NASDAQ:HSDT or “the Company"), formerly Helius Medical Technologies, Inc., today announced it has entered into agreements with Coinbase, BitGo and [...]
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
10/10/2025
-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD program, CTX460, is the first investigational candidate to emerge from the [...]
Alignment Healthcare Maintains High 2026 Star Ratings from Medicare, 100% of Members Enrolled in Plans Rated 4 Stars or Higher for Second Consecutive Year
10/10/2025
Medicare Advantage company adds second 5-star HMO contract in Nevada, Texas HMO earns 4.5 stars in first year ORANGE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) announced today [...]
Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors
10/10/2025
Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), [...]
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
10/10/2025
HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to [...]
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
10/10/2025
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close [...]
Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility
10/10/2025
CHICAGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has purchased an [...]
Annovis Announces $6 Million Registered Direct Offering of Common Stock
10/10/2025
MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities
10/10/2025
Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
WORK Medical Technology Group LTD Granted Additional 180-Day Period to Regain Nasdaq Compliance
10/10/2025
Hangzhou, China, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
The Korean Trio Shines Out at ECRM for Its Detoxifying Nutraceuticals
10/10/2025
Anathapindika Health’s Signature Nutraceuticals Draw Attention, Impress Buyers at the September Nutraceutical Conference — Just in Time to Gain Momentum for the Back-to-School Season Fort Lauderdale, FL, Oct. 10, 2025 ( [...]
NTG Nordic Transport Group A/S - Q3 2025 Conference Call
10/10/2025
NTG Nordic Transport Group A/S – Q3 2025 Conference Call We expect to release the Q3 2025 interim results of NTG Nordic Transport Group on the evening of November 10, 2025. A webcast and conference call will be held in [...]
Shape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene Therapy at the European Society of Gene & Cell Therapy 32nd Annual Congress
10/10/2025
Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson's Disease-critical substantia [...]
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
10/10/2025
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR [...]
NeuroVigil’s iBrain™ in TIME’s “Best Inventions of 2025”
10/10/2025
SAN FRANCISCO and WATERLOO, Ontario and MONTREAL and LEIPZIG, Germany, Oct. 09, 2025 (GLOBE NEWSWIRE) -- TIME has announced today that Silicon Valley-based Neurotechnology Powerhouse NeuroVigil’s iBrain™ has been [...]
Executive Wellness Retreats: Grey Matters International Announces Expansion of Neuroscience-Based Programs
09/10/2025
Tulsa, Oklahoma , Oct. 09, 2025 (GLOBE NEWSWIRE) -- Grey Matters International, Inc. , a neuroscience-driven mental health organization founded by Kevin J. Fleming, Ph.D., today announced the expansion of its executive [...]
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
09/10/2025
ACTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced [...]
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
09/10/2025
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 [...]

Pages